These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22764764)

  • 21. Target therapy in elderly breast cancer patients.
    Carli P; Turchet E; Quitadamo D; Spada A; Miolo G; Lamaj E; Spazzapan S; Di Lauro V; Dolcetti R; Veronesi A; Crivellari D
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):422-31. PubMed ID: 22257652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.
    Zhang Y; Zhang J; Liu C; Du S; Feng L; Luan X; Zhang Y; Shi Y; Wang T; Wu Y; Cheng W; Meng S; Li M; Liu H
    Cancer Lett; 2016 Nov; 382(2):176-185. PubMed ID: 27597738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis.
    Nasrazadani A; Brufsky A
    Future Oncol; 2020 Mar; 16(7):247-254. PubMed ID: 32057254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
    Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
    J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Determinants of Response to HER Kinase Inhibition in
    Smyth LM; Piha-Paul SA; Won HH; Schram AM; Saura C; Loi S; Lu J; Shapiro GI; Juric D; Mayer IA; Arteaga CL; de la Fuente MI; Brufksy AM; Spanggaard I; Mau-Sørensen M; Arnedos M; Moreno V; Boni V; Sohn J; Schwartzberg LS; Gonzàlez-Farré X; Cervantes A; Bidard FC; Gorelick AN; Lanman RB; Nagy RJ; Ulaner GA; Chandarlapaty S; Jhaveri K; Gavrila EI; Zimel C; Selcuklu SD; Melcer M; Samoila A; Cai Y; Scaltriti M; Mann G; Xu F; Eli LD; Dujka M; Lalani AS; Bryce R; Baselga J; Taylor BS; Solit DB; Meric-Bernstam F; Hyman DM
    Cancer Discov; 2020 Feb; 10(2):198-213. PubMed ID: 31806627
    [No Abstract]   [Full Text] [Related]  

  • 26. Lapatinib-associated toxicity and practical management recommendations.
    Moy B; Goss PE
    Oncologist; 2007 Jul; 12(7):756-65. PubMed ID: 17673607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU.
    Dhillon S
    Clin Drug Investig; 2019 Feb; 39(2):221-229. PubMed ID: 30607817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Afatinib in the treatment of breast cancer.
    Hurvitz SA; Shatsky R; Harbeck N
    Expert Opin Investig Drugs; 2014 Jul; 23(7):1039-47. PubMed ID: 24870559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An overview of HER-targeted therapy with lapatinib in breast cancer.
    McArthur H
    Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neratinib (Nerlynx) for HER2-positive breast cancer.
    Med Lett Drugs Ther; 2018 Jan; 60(1539):23. PubMed ID: 29364199
    [No Abstract]   [Full Text] [Related]  

  • 31. The development of HKI-272 and related compounds for the treatment of cancer.
    Wissner A; Mansour TS
    Arch Pharm (Weinheim); 2008 Aug; 341(8):465-77. PubMed ID: 18493974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lapatinib in breast cancer: clinical experiences and future perspectives.
    Giampaglia M; Chiuri VE; Tinelli A; De Laurentiis M; Silvestris N; Lorusso V
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S72-9. PubMed ID: 21129615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treating the HER2 pathway in early and advanced breast cancer.
    Pegram MD
    Hematol Oncol Clin North Am; 2013 Aug; 27(4):751-65, viii. PubMed ID: 23915743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer.
    Bose P; Ozer H
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1735-51. PubMed ID: 19780706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current and future anti-HER2 therapy in breast cancer.
    Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
    J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Acquired
    Hanker AB; Brewer MR; Sheehan JH; Koch JP; Sliwoski GR; Nagy R; Lanman R; Berger MF; Hyman DM; Solit DB; He J; Miller V; Cutler RE; Lalani AS; Cross D; Lovly CM; Meiler J; Arteaga CL
    Cancer Discov; 2017 Jun; 7(6):575-585. PubMed ID: 28274957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.
    Sequist LV; Besse B; Lynch TJ; Miller VA; Wong KK; Gitlitz B; Eaton K; Zacharchuk C; Freyman A; Powell C; Ananthakrishnan R; Quinn S; Soria JC
    J Clin Oncol; 2010 Jun; 28(18):3076-83. PubMed ID: 20479403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neratinib Approved for HER2+ Breast Cancer.
    Cancer Discov; 2017 Sep; 7(9):OF1. PubMed ID: 28778899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neratinib and capecitabine for breast cancer brain metastases.
    Stirrups R
    Lancet Oncol; 2019 Apr; 20(4):e197. PubMed ID: 30910514
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.